Skip to content
Open access

COVID-19 vaccination timing, relative to acute COVID-19, and subsequent risk of long COVID

Jul 2026 · EBioMedicine · Vol 130, pp. 106382 · 0 citations · 42 references
Medicine

TL;DR

It is found that COVID-19 vaccination was protective against Long COVID, and a significant waning of this protection within seven months after vaccination was observed.

Abstract

Summary Background Vaccination is a vital tool in preventing acute COVID-19 and may confer additional protection against Long COVID, although it is unclear whether this protection wanes over time. Methods We assessed electronic health record (EHR) data from a national, retrospective cohort of patients, comparing the 12-month cumulative incidence of Long COVID (ICD-10 code U09.9) among (A) patients who were vaccinated versus unvaccinated (two or more versus zero doses) and (B) patients diagnosed with acute COVID-19 1–3 months, 3–5 months, or 5–7 months after vaccination. Findings In our binary cohort (n = 519,980), we found that patients who were vaccinated had a lower risk of Long COVID (adjusted risk ratio 0.84 (0.81, 0.88)) or mortality (adjusted risk ratio 0.83 (0.81, 0.86)) than patients who were unvaccinated. In our longitudinal cohort (n = 1,085,291), we did not find significant heterogeneity in Long COVID risk during the seven months following vaccination. Interpretation We found that COVID-19 vaccination was protective against Long COVID, and we did not observe a significant waning of this protection within seven months after vaccination. Funding This research was financially supported by the 10.13039/100000060National Institute of Allergy and Infectious Diseases (1K01AI182501 to Zachary Butzin-Dozier) and a Global Development grant (OPP1165144) from the 10.13039/100000865Bill & Melinda Gates Foundation to the 10.13039/100005595University of California, Berkeley, CA, USA. Individual authors were supported by the following funding sources: 10.13039/100000025NIMHR01131542 (PI Rena C. Patel), Jerrod Anzalone is supported by the 10.13039/100000057National Institute of General Medical Sciences, U54 GM115458, which funds the Great Plains IDeA-CTR Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Read PDF

Similar papers

Open access Aug 2026

Long-term adverse effects following COVID-19 vaccination

The most commonly reported long-term adverse effects after COVID-19 vaccination were chronic fatigue, cognitive impairment, and menstrual irregularity.

J. Aldali, S. Meo · 0 citations
Open access Aug 2026

Association between post-vaccination adverse events and subsequent COVID-19 booster uptake in the Netherlands.

A lower likelihood of subsequent COVID-19 booster uptake after experiencing systemic AE, particularly when severe or prolonged, or when experiencing a severe local AE is found, underscore the need to address experienced AE in communication strategies, as this may influence the success of vaccination campaigns.

Anne J. Huiberts, Maud M J Smits, C. Hoeve et al. · 0 citations
Open access Aug 2026

Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study (2023-2024).

In this population-based cohort, completion of the 3-dose BNT162b2 primary series was associated with substantially lower rates of COVID-19-attributed SARI among children aged 6 months to 4 years.

I. N. Schrarstzhaupt, F. A. Diaz-Quijano · 0 citations
Open access Aug 2026

COVID-19 Vaccination and Risk of Post-COVID-19 Cardiovascular Disease: A Population-Based Cohort and Target Trial Emulation Study.

Findings support COVID-19 vaccination as an important component of strategies to reduce the burden of post-COVID-19 CVD while highlighting the need for further studies to clarify the mechanisms underlying these associations.

B. Seboka, D. Magliano, T. Marwick et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.